Article | March 14, 2019

Assessing And Navigating Testing For Parenteral Packaging And Delivery Systems: Container Closure Integrity

By Jennifer Riter

Assessing And Navigating Testing For Parenteral Packaging And Delivery Systems

Container Closure Integrity (CCI) is a key area that needs to be evaluated in the development phase of drug products. CCI is defined as the ability of a package to prevent product loss, to block the ingress of microorganisms, and to limit entry of detrimental gases or other substances over the shelf life – ensuring that the drug product meets all necessary safety and quality standards. This article discusses the chapters in USP <1207> Package Integrity Evaluation – Sterile Products, which covers CCI and different methods of selection and validation.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

West Pharmaceutical Services, Inc.